Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice

Authors

  • Ali Badiee Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
  • Ali Khamesipour Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
  • Azam Abbasi Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
  • Mahmoud Reza Jaafari Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran 2 Biotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
  • Nazanin Biari Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
  • Omid Chavoshian Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
  • Seyed Amir Jalali Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
  • Zahra Saberi Nanotechnology Research Center, School of Pharmacy, Mashhad, University of Medical Sciences, Mashhad, Iran
Abstract:

  Objective(s): Soluble Leishmania antigens (SLA) provide suitable protection against leishmaniasis in murine model when delivered by an appropriate delivery system. Liposomes have been shown to be suitable vaccine delivery systems against leishmaniasis, however, the phospholipase-A (PLA) activity of SLA is a drawback to prepare a stable liposomal SLA. One strategy to overcome this problem might be using a lipid which is resistant to PLA activity of SLA such as sphingomyelin (SM). The aim of this study was to evaluate the effect of stable SM liposomes containing SLA on the immune response induced against leishmaniasis in BALB/c mice .   Materials and Methods: BALB/c mice were immunized subcutaneously, three times with 2-week intervals, with SLA, SM-liposome-SLA, empty liposome or buffer. As criteria for protection, footpads swelling at the site of challenge and foot parasite loads were assessed. The immune responses were also evaluated by determination of IgG subtypes and the level of IFN-γ and IL-4 in cultured splenocytes. Results: The group of mice receiving SM-liposome-SLA, showed a significant large footpad swelling, higher parasite burden in foot and higher IL-4 level compared to the group immunized with buffer. In terms of IgG and IgG isotypes, there was no significant difference between the mice receiving SM-liposome-SLA and the mice that received buffer. Moreover, the immune response induced by SM-liposome-SLA showed no significant difference compared with the one caused by SLA alone. Conclusion: It is concluded that SM-liposome-SLA is not an appropriate strategy to induce Th1 immune response and protect the mice against Leishmaniasis; however, SM-liposomes could be suitable vaccine delivery systems when a Th2 response is needed.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

sphingomyelin liposomes containing soluble leishmania major antigens induced strong th2 immune response in balb/c mice

objective(s): soluble leishmania antigens (sla) provide suitable protection against leishmaniasis in murine model when delivered by an appropriate delivery system. liposomes have been shown to be suitable vaccine delivery systems against leishmaniasis, however, the phospholipase-a (pla) activity of sla is a drawback to prepare a stable liposomal sla. one strategy to overcome this problem might ...

full text

DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice

Objective(s): Leishmaniasis is a complex parasitic disease that represents a major public health problem. Despite numerous attempts over the past decades, yet there is no effective vaccine against human leishmaniasis probably due to the lack of suitable adjuvants. In this study, a first generation liposomal-based Leishmania vaccine was developed using soluble Leishmania major antigens (SLA) and...

full text

dda/tdb liposomes containing soluble leishmania major antigens induced a mixed th1/th2 immune response in balb/c mice

objective(s): leishmaniasis is a complex parasitic disease that represents a major public health problem. despite numerous attempts over the past decades, yet there is no effective vaccine against human leishmaniasis probably due to the lack of suitable adjuvants. in this study, a first generation liposomal-based leishmania vaccine was developed using soluble leishmania major antigens (sla) and...

full text

Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation

Background: Cationic immune stimulating complexes (PLUSCOMs) are particulate antigen delivery systems. PLUSCOMs consist of cationic immunostimulatory complexes (ISCOMs) derivatives and are able to elicit in vivo T cell responses against an antigen. Objective: To evaluate the effects of PLUSCOMs containing Leishmaniamajor antigens (SLA) on the type of immune response generated in the murine mod...

full text

Heat Shock Proteins Enriched-Promastigotes of Leishmania major Inducing Th2 Immune Response in BALB/c Mice

Background: Heat shock proteins (HSP) are highly conserved molecules with many immunological functions. They are highly immunogenic with important role in cancer immunotherapy and in vaccine development against infectious diseases. As adjuvant, HSP can augment the immunogenicity of weak antigens and can stimulate antigen presenting cells. Although vaccines have been successful for many infec...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 16  issue 9

pages  965- 972

publication date 2013-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023